Your browser is no longer supported. Please, upgrade your browser.
Settings
ATNX Athenex, Inc. daily Stock Chart
ATNX [NASD]
Athenex, Inc.
Index- P/E- EPS (ttm)-2.21 Insider Own9.90% Shs Outstand67.79M Perf Week-0.36%
Market Cap945.67M Forward P/E- EPS next Y-1.32 Insider Trans-13.31% Shs Float45.95M Perf Month26.13%
Income-145.40M PEG- EPS next Q-0.31 Inst Own32.20% Short Float11.77% Perf Quarter8.73%
Sales76.60M P/S12.35 EPS this Y6.30% Inst Trans0.33% Short Ratio14.30 Perf Half Y36.16%
Book/sh1.60 P/B8.72 EPS next Y26.40% ROA-66.60% Target Price25.20 Perf Year-17.94%
Cash/sh1.05 P/C13.26 EPS next 5Y- ROE-109.10% 52W Range9.38 - 20.90 Perf YTD9.93%
Dividend- P/FCF- EPS past 5Y- ROI-68.20% 52W High-33.25% Beta-
Dividend %- Quick Ratio1.90 Sales past 5Y- Gross Margin27.40% 52W Low48.72% ATR0.71
Employees575 Current Ratio2.20 Sales Q/Q-33.10% Oper. Margin- RSI (14)64.87 Volatility4.16% 6.13%
OptionableYes Debt/Eq0.44 EPS Q/Q-344.20% Profit Margin- Rel Volume1.06 Prev Close13.93
ShortableYes LT Debt/Eq0.43 EarningsMay 09 BMO Payout- Avg Volume378.40K Price13.95
Recom1.80 SMA2016.30% SMA5016.65% SMA2004.93% Volume402,781 Change0.14%
May-02-19Initiated Oppenheimer Outperform $20
Mar-29-19Initiated SunTrust Buy $20
Nov-15-18Upgrade JP Morgan Neutral → Overweight
Oct-25-18Initiated Ladenburg Thalmann Buy $27
Mar-06-18Initiated Needham Buy $30
Oct-18-17Initiated JP Morgan Neutral $22.20
Sep-18-17Initiated Credit Suisse Outperform $25
Sep-15-17Initiated RBC Capital Mkts Outperform $35
May-14-19 02:21PM  Edited Transcript of ATNX earnings conference call or presentation 9-May-19 12:00pm GMT Thomson Reuters StreetEvents
May-09-19 03:23PM  Athenex, Inc. (ATNX) Q1 2019 Earnings Call Transcript Motley Fool
09:07AM  Athenex: 1Q Earnings Snapshot Associated Press
May-06-19 04:31PM  Why Bausch Health Companies, Aquantia, and Athenex Jumped Today Motley Fool +28.36%
10:20AM  Athenex just raised $100 million. Here's what it means American City Business Journals
08:00AM  Athenex Announces $100 Million Private Placement GlobeNewswire
May-05-19 01:44PM  Hedge Funds Have Never Been This Bullish On Athenex, Inc. (ATNX) Insider Monkey
May-03-19 09:12AM  Athenex Announces Promising Early and Complete Response Data from a Clinical Study of Oraxol in Cutaneous Angiosarcoma GlobeNewswire
Apr-25-19 07:00AM  Athenex, Inc. to Report First Quarter 2019 Earnings Results on May 9, 2019 GlobeNewswire
Apr-23-19 07:00AM  Athenex Announces Abstracts Accepted for Presentation at the 2019 American Society of Clinical Oncology Annual Meeting GlobeNewswire
Apr-02-19 07:00AM  Athenex Announces Appointment of John Koh as a New Board Member GlobeNewswire
Apr-01-19 01:20PM  Weekly CEO Buys Highlight GuruFocus.com
Mar-29-19 04:15PM  Athenex Announces Appointment of Jordan S. Kanfer to Board of Directors GlobeNewswire
09:15AM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares GuruFocus.com
Mar-28-19 07:00AM  Athenex Announces Appointment of Dr. Daniel Von Hoff as Chairman of the Scientific Advisory Board of Axis Therapeutics Limited GlobeNewswire
Mar-27-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,000 of Shares GuruFocus.com
Mar-26-19 07:15AM  New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Mar-25-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $124,500 of Shares GuruFocus.com
Mar-21-19 08:30AM  Athenex Announces Xiangxue Life Sciences Receives IND Allowance from Chinas National Medical Products Administration for Cancer Immunotherapy Drug Candidate GlobeNewswire
08:30AM  Athenex Announces Expansion of Board of Directors GlobeNewswire
Mar-20-19 09:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $126,000 of Shares GuruFocus.com
Mar-19-19 08:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $226,212 of Shares GuruFocus.com
Mar-15-19 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $141,240 of Shares GuruFocus.com
Mar-14-19 01:29AM  Edited Transcript of ATNX earnings conference call or presentation 11-Mar-19 12:30pm GMT Thomson Reuters StreetEvents
Mar-13-19 12:04PM  The moment Athenex executives and investors have been waiting for is almost here American City Business Journals
07:00AM  SunGen Pharma and Athenex Pharmaceutical Division Announce Busulfan Injection Product Launch GlobeNewswire
Mar-11-19 04:14PM  Athenex, Inc. (ATNX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:10AM  Athenex: 4Q Earnings Snapshot Associated Press
07:00AM  Athenex, Inc. Announces Fourth Quarter and Year Ended December 31, 2018 Financial Results and Provides Corporate Update GlobeNewswire
Mar-08-19 07:00AM  Athenex to Present Preclinical Data of Oraxol in the Treatment of Angiosarcoma at the American Association for Cancer Research Annual Meeting 2019 GlobeNewswire
Mar-07-19 04:05AM  Athenex Regains Rights to KX2-391 in China GlobeNewswire
Mar-04-19 01:35PM  Almirall and Athenex Announce Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting PR Newswire
08:47AM  Shares of Athenex up 3.8% after Phase 3 studies for actinic keratosis treatment meet primary endpoints MarketWatch
07:00AM  Athenex Announces Positive Topline Results from Two Phase III Studies of KX2-391 Ointment 1% Featured in Late Breaker Program at the 2019 American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-25-19 07:50AM  New Research Coverage Highlights The Wendy's, Rite Aid, Invesco, LendingClub, Diodes, and Athenex Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
07:00AM  Athenex to Host Conference Call with Key Opinion Leader Following Oral Presentation of Phase III Results of KX2-391 Ointment in the Treatment of Actinic Keratosis at the American Academy of Dermatology Annual Meeting GlobeNewswire
Feb-14-19 07:00AM  Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019 GlobeNewswire
Feb-04-19 07:00AM  Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting GlobeNewswire
Jan-16-19 04:26PM  Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings Zacks
Jan-10-19 03:19PM  Athenex Completes Enrollment Target for Breast Cancer Study Zacks
05:05AM  Buffalo startups surpassed $200 million in VC and angel funding in 2018 American City Business Journals
Jan-09-19 07:00AM  Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study GlobeNewswire
Jan-04-19 03:26AM  Teresa Bair talks about the big year ahead for Athenex American City Business Journals
Jan-03-19 07:00AM  Chongqing Jingdong Pharmaceutical and Athenex Announce a Strategic Partnership and Licensing Agreement to Develop and Commercialize KX2-391 in China GlobeNewswire -5.56%
Dec-26-18 07:00AM  Athenex Pharmaceutical Division, an Athenex, Inc. Company, Launches Levothyroxine Sodium for Injection GlobeNewswire +15.68%
Dec-20-18 01:04PM  What Kind Of Shareholders Own Athenex, Inc. (NASDAQ:ATNX)? Simply Wall St. -8.61%
Dec-13-18 09:47AM  Company News For Dec 13, 2018 Zacks -6.62%
Dec-11-18 12:46PM  CORRECTION: Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer GlobeNewswire
07:00AM  Athenex Announces Positive Second Cohort Results of Oraxol-plus-Ramucirumab Phase 1b Clinical Trial in Gastric Cancer GlobeNewswire
Dec-06-18 08:10AM  Recent Analysis Shows Athenex, National CineMedia, Macy's, Manulife Financial, CBS, and Strategic Education Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:00AM  Athenex to Host an R&D Day on December 17 in New York GlobeNewswire
Nov-29-18 07:07AM  Athenex Announces Licensing Agreement with PharmaEssentia for Rights to Oradoxel (Oral Docetaxel) in Certain Asian Territories GlobeNewswire
Nov-26-18 07:00AM  Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1 GlobeNewswire
Nov-19-18 06:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $117,500 of Shares GuruFocus.com
Nov-14-18 07:15PM  Athenex Inc (ATNX) CEO and Chairman of the Board Johnson Yiu Nam Lau Bought $418,800 of Shares GuruFocus.com -12.14%
03:26PM  Edited Transcript of ATNX earnings conference call or presentation 14-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
07:14AM  Athenex: 3Q Earnings Snapshot Associated Press
07:00AM  Athenex, Inc. Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Nov-01-18 07:00AM  Athenex, Inc. to Report Third Quarter Earnings Results on November 14, 2018 GlobeNewswire
Oct-29-18 07:00AM  Athenex Announces FDA Allowance of Investigational New Drug Application of Eribulin ORA to Begin Clinical Trials GlobeNewswire
Oct-26-18 07:55AM  Recent Analysis Shows Prologis, Delek Logistics Partners, Fabrinet, New York Mortgage Trust, Petroleo Brasileiro S.A.- Petrobras, and Athenex Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Oct-22-18 07:00AM  ESMO 2018: Athenex Presented Encouraging Clinical Trial Efficacy and Safety Results of Oraxol in the Treatment of Metastatic Breast Cancer GlobeNewswire
Oct-16-18 08:07AM  Athenex to Present Positive Data of Oraxol Clinical Trial in Breast Cancer at the ESMO 2018 Congress GlobeNewswire +10.36%
Oct-15-18 07:00AM  Athenex and Xiangxue Life Sciences Announce Preliminary Results of Patients Receiving T-Cell Receptor Affinity Enhancing Specific T-Cell Therapy (TAEST) Showed Encouraging Positive Clinical Signals GlobeNewswire
Sep-25-18 07:40AM  Report: Developing Opportunities within RLJ Lodging Trust, Solar Capital, Athenex, Bonanza Creek Energy, Mueller Industries, and Corporate Office Properties Trust Future Expectations, Projections Moving into 2018 GlobeNewswire
Sep-12-18 08:00AM  Athenex and its Collaborative Partner, Hanmi Pharmaceutical, Announce Strategic Realignment of their Joint Projects GlobeNewswire
Sep-05-18 07:00AM  Athenex Announces Positive Recommendation by the Drug Safety Monitoring Board Upon the Second Interim Analysis and to Continue the Oraxol Phase III Program GlobeNewswire
Aug-31-18 02:19PM  Edited Transcript of ATNX earnings conference call or presentation 14-Aug-18 1:00pm GMT Thomson Reuters StreetEvents
Aug-20-18 08:00AM  Athenex Appoints Randoll Sze as Chief Financial Officer GlobeNewswire
Aug-14-18 07:19AM  Athenex: 2Q Earnings Snapshot Associated Press -6.02%
07:00AM  Athenex, Inc. to Host Earnings Call ACCESSWIRE
07:00AM  Athenex, Inc. Announces Second Quarter 2018 Results and Provides Corporate Update GlobeNewswire
Aug-13-18 07:29AM  Athenex Pharma Solutions, an Athenex, Inc. Company, Launches Compounded Vasopressin Injection in Ready-to-Use Premix IV Bags GlobeNewswire
Aug-09-18 09:00AM  Athenex Pharmaceutical Division Receives FDA Clearance to Import Potassium Chloride Injection Concentrate to Address U.S. Drug Shortage GlobeNewswire
Aug-03-18 08:00AM  Athenex, Inc. to Report Second Quarter Earnings Results on August 14, 2018 GlobeNewswire
Jul-31-18 08:20AM  Report: Exploring Fundamental Drivers Behind Athenex, Crocs, Civeo, PLDT, Heartland Financial, and Prologis New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jul-26-18 07:00AM  Athenex Announces That Two Phase 3 Pivotal Efficacy Studies of KX2-391 in Actinic Keratosis Achieved Their Primary Endpoints GlobeNewswire
Jul-25-18 10:05AM  Is Athenex (ATNX) Stock Outpacing Its Medical Peers This Year? Zacks
Jul-18-18 09:00AM  Athenex Announces Axis Therapeutics Has Entered into a MOU with the Hong Kong Polytechnic University to Set Up a Joint Research Center on Cancer Immunotherapy GlobeNewswire
Jul-09-18 06:30AM  Athenex Names Timothy Cook as Senior Vice President of Global Commercial Oncology GlobeNewswire
Jul-02-18 06:30AM  Athenex Announces Pipeline Expansion Initiatives in Conjunction with a Strategic Investment of $100 million by Perceptive Advisors GlobeNewswire
Jun-19-18 03:18AM  Edited Transcript of ATNX earnings conference call or presentation 14-May-18 1:00pm GMT Thomson Reuters StreetEvents
Jun-15-18 07:00AM  Athenex Announces Appointment to Board of Directors GlobeNewswire
Jun-04-18 08:00AM  Athenex Names Christina Wang as Vice President of Clinical Operations and Corporate Development, Asia Pacific GlobeNewswire
07:00AM  Athenex Announces Poster Presentations at ASCO Annual Meeting GlobeNewswire
May-31-18 06:10PM  Athenex Incs (NASDAQ:ATNX) Shift From Loss To Profit Simply Wall St.
May-23-18 09:31AM  Did Athenex Incs (NASDAQ:ATNX) Earnings Growth Outperform The Industry? Simply Wall St.
May-21-18 08:00AM  Athenex to Present at UBS Global Healthcare Conference GlobeNewswire
May-18-18 12:18AM  Lessons from Athenex's end-of-year reports American City Business Journals
May-14-18 07:34PM  Athenex: 1Q Earnings Snapshot Associated Press
07:00AM  Athenex, Inc. Announces First Quarter 2018 Results GlobeNewswire
May-08-18 08:00AM  Athenex to Present at Deutsche Banks 43rd Annual Health Care Conference GlobeNewswire
May-03-18 08:00AM  Athenex, Inc. to Report First Quarter Earnings Results on May 14, 2018 GlobeNewswire
Apr-30-18 06:30AM  Athenex, Inc. Announces Transition of James Zukin from Board of Directors to Advisory Role GlobeNewswire
Apr-27-18 04:58PM  What Do Athenex Inc (NASDAQ:ATNX) Insiders Know That You Dont? Simply Wall St.
01:07PM  Why a cohort of experts from Hong Kong PolyU are visiting Buffalo American City Business Journals
Apr-20-18 07:40AM  Blog Exposure - FDA Granted Fast Track Designation to Calithera Biosciences CB-839 in Combination with Cabozantinib for Advanced Renal Cell Carcinoma Treatment ACCESSWIRE
Apr-19-18 08:00AM  Athenex, Inc. Receives U.S. FDA Orphan Drug Designation for Oraxol for the Treatment of Angiosarcoma GlobeNewswire
Apr-18-18 08:10AM  Report: Exploring Fundamental Drivers Behind Exponent, Monotype Imaging, Athenex, State Street, Heartland Financial, and IRSA Inversiones Y Representaciones S.A New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-09-18 08:00AM  Cerecor Appoints Simon Pedder to its Board of Directors Marketwired
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of various therapies for the treatment of cancer and related conditions in North America and Asia. It operates in three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oraxol, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in advanced malignances and gastric cancer; and Oratecan, an oral dosage form of irinotecan that is in a Phase I study for the treatment of metastatic colorectal cancer, glioblastoma, lung, ovarian, cervical, upper gastrointestinal, and pancreatic cancer. Its Orascovery product candidates also comprise Oradoxel, an oral dosage form of docetaxel, which is in Phase I clinical study for breast, lung, prostate, gastric, and head and neck cancers; Oratopo, an oral dosage form of topotecan that is Phase I clinical trial to treat lung, ovarian, and cervical cancer; and oral eribulin, an intravenous anticancer drug to treat certain patients with breast cancer and advanced liposarcoma. In addition, the company offers Src Kinase product candidates comprising KX2-391 ointments for actinic keratosis, skin cancers, and psoriasis; KX-01 oral for solid and liquid tumors; and KX2-361 for glioblastoma multiforme. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome P450 enzymes within the gastrointestinal tract; T Cell Receptor Engineered T Cell, a cell-based immunotherapy; and Pegtomarginase, an arginine deprivation therapy product. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was founded in 2003 and is headquartered in Buffalo, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PERCEPTIVE ADVISORS LLC10% OwnerMay 06Buy12.71100,0001,271,1489,196,022May 08 05:04 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardApr 24Option Exercise4.5510,00045,5003,021,959Apr 25 04:08 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 28Buy12.4010,000124,0002,996,385Mar 28 04:14 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 27Buy12.4010,000124,0002,986,385Mar 27 04:23 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 25Buy12.4510,000124,5002,976,385Mar 25 04:08 PM
Zuo William WeiPresident, China DivisionMar 25Buy12.471,00012,4701,118,777Mar 26 04:07 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 21Buy12.571,00012,5702,966,385Mar 21 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 20Buy12.0010,500126,0002,965,385Mar 20 04:38 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 19Buy12.1318,649226,2122,954,885Mar 19 05:03 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 18Buy12.524,00050,0802,936,236Mar 18 04:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 15Buy11.7712,000141,2402,932,236Mar 15 05:08 PM
Trainor-Degirolamo SheldonDirectorMar 15Sale11.7754,079636,510611,333Mar 18 04:21 PM
Trainor-Degirolamo SheldonDirectorMar 14Sale11.79671665,412Mar 18 04:21 PM
Trainor-Degirolamo SheldonDirectorMar 13Sale11.7745,915540,420665,418Mar 14 04:11 PM
Zhang Song-YiDirectorMar 13Sale11.824,43252,3863,938,613Mar 14 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 12Buy11.802,81433,2052,920,236Mar 12 04:55 PM
Zhang Song-YiDirectorMar 12Sale11.8983,381991,4003,943,045Mar 14 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardMar 11Buy11.7810,000117,8002,917,422Mar 11 04:53 PM
Zhang Song-YiDirectorMar 11Sale11.8532,240382,0444,026,426Mar 14 04:15 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardDec 20Option Exercise4.5510,00045,5002,907,422Dec 20 05:26 PM
Zhang Song-YiDirectorNov 30Sale13.10600,0007,860,0004,058,666Dec 03 04:14 PM
Zhang Song-YiDirectorNov 29Sale13.23400,0005,292,0004,658,666Dec 03 04:14 PM
Kwan RudolfEVP, Chief Medical OfficerNov 19Buy11.701,00011,69798,224Nov 19 04:09 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 19Buy11.7510,000117,5002,897,422Nov 19 04:05 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardNov 14Buy10.4740,000418,8002,887,422Nov 14 06:29 PM
Kwan RudolfEVP, Chief Medical OfficerNov 14Buy10.4910,000104,90092,224Nov 14 06:20 PM
WU JINNDirectorNov 14Buy10.2510,000102,500321,208Nov 14 06:16 PM
Pedder SimonSee RemarksNov 14Buy10.262,90829,8303,908Nov 14 06:10 PM
YORDON JEFFREYSee RemarksNov 14Buy10.499,50099,655198,209Nov 14 05:25 PM
Sze RandollChief Financial OfficerNov 14Buy10.261,00010,2551,000Nov 14 05:20 PM
Kwan RudolfEVP, Chief Medical OfficerNov 14Buy10.355,00051,74897,224Nov 15 04:07 PM
WU JINNDirectorOct 15Buy13.4712,500168,375311,208Oct 15 05:40 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 27Buy15.662,00031,3202,847,422Sep 27 04:21 PM
WU JINNDirectorSep 11Option Exercise4.5532,000145,600298,708Sep 11 04:31 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 07Option Exercise4.2520,00085,0002,845,422Sep 07 06:22 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardSep 06Buy15.845,00079,2002,825,422Sep 07 06:45 AM
WU JINNDirectorSep 06Buy16.092,50040,220266,708Sep 07 04:21 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 30Option Exercise4.2520,00085,0002,820,422Aug 30 06:44 PM
Zhang Song-YiDirectorAug 29Sale16.5644,686740,0005,058,666Aug 30 06:28 PM
Zhang Song-YiDirectorAug 28Sale16.956,343107,5145,103,352Aug 30 06:28 PM
Zhang Song-YiDirectorAug 27Sale17.0630,302516,9525,109,695Aug 28 06:01 PM
LAU JOHNSON YIU NAMCEO and Chairman of the BoardAug 24Option Exercise4.2520,00085,0002,800,422Aug 24 04:10 PM
Zhang Song-YiDirectorAug 24Sale17.1723,137397,2625,139,997Aug 28 06:01 PM
Zhang Song-YiDirectorAug 23Sale17.2825,748444,9255,163,134Aug 27 04:13 PM
Zhang Song-YiDirectorAug 22Sale17.3856,176976,3395,188,882Aug 23 04:22 PM
Zhang Song-YiDirectorAug 21Sale17.0746,558794,7455,245,058Aug 23 04:22 PM
WU JINNDirectorAug 20Buy17.205,00086,000264,208Aug 21 05:26 PM
Zhang Song-YiDirectorAug 20Sale17.1146,000787,0605,291,616Aug 21 05:23 PM
Zhang Song-YiDirectorAug 17Sale17.1870,1331,204,8855,337,616Aug 21 05:23 PM
Zhang Song-YiDirectorAug 16Sale16.7461,2071,024,6055,449,862Aug 17 04:19 PM
Zhang Song-YiDirectorAug 15Sale16.5343,845724,7585,511,069Aug 17 04:19 PM
Trainor-Degirolamo SheldonDirectorJun 06Sale16.8112,401208,461711,333Jun 07 04:18 PM
Trainor-Degirolamo SheldonDirectorJun 05Sale16.8257,421965,821723,734Jun 06 04:06 PM
Trainor-Degirolamo SheldonDirectorJun 04Sale16.8131,633531,751781,155Jun 05 04:07 PM
Zhang Song-YiDirectorMay 30Sale16.1129,416473,8925,733,108Jun 01 04:10 PM
Zhang Song-YiDirectorMay 29Sale16.0770,5841,134,2855,762,524Jun 01 04:10 PM
Zhang Song-YiDirectorMay 25Sale16.515,73994,7515,833,108May 29 04:47 PM
Trainor-Degirolamo SheldonDirectorMay 24Sale16.888,858149,523812,788May 30 04:19 PM
Zhang Song-YiDirectorMay 24Sale16.763,85364,5765,838,847May 29 04:47 PM
Trainor-Degirolamo SheldonDirectorMay 23Sale17.0314,584248,366821,646May 24 04:12 PM
Trainor-Degirolamo SheldonDirectorMay 22Sale17.005,41992,123836,230May 24 04:12 PM